Heterogeneous PSMA expression on circulating tumor cells - a potential basis for stratification and monitoring of PSMA-directed therapies in prostate cancer

The prostate specific membrane antigen (PSMA) is the only clinically validated marker for therapeutic decisions in prostate cancer (PC). Characterization of circulating tumor cells (CTCs) obtained from the peripheral blood of PC patients might provide an alternative to tissue biopsies called “liquid...

Descripción completa

Detalles Bibliográficos
Autores principales: Gorges, Tobias M., Riethdorf, Sabine, von Ahsen, Oliver, Nastały, Paulina, Röck, Katharina, Boede, Marcel, Peine, Sven, Kuske, Andra, Schmid, Elke, Kneip, Christoph, König, Frank, Rudolph, Marion, Pantel, Klaus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5085200/
https://www.ncbi.nlm.nih.gov/pubmed/27145459
http://dx.doi.org/10.18632/oncotarget.9004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5085200/
https://www.ncbi.nlm.nih.gov/pubmed/27145459
http://dx.doi.org/10.18632/oncotarget.9004

Ejemplares similares